Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX), an oncology company focusing on genetic and epigenetic drivers of cancer, today announced it will present data on its tyrosine kinase inhibitor, MGCD516, at the ESMO 2015 European Cancer Congress being held in Vienna, Austria from September 25-29, 2015.
Data from the study titled, "A First-in-Human Phase 1/1b Study of Receptor Tyrosine Kinase (RTK) Inhibitor, MGCD516, in Patients with Advanced Solid Tumors" will be presented during the "Early Drug Development" poster session on Sunday, September 27, 2015 from 4:45 – 6:45 PM CEST/7:45 – 9:45 AM PDT at the Messe Wien Exhibition and Congress Centre, Hall C.
"MGCD516 is a potent, orally bioavailable inhibitor of key pathways that drive tumor growth. Specifically, MGCD516 targets driver mutations including RET, Trk and DDR gene alterations, which occur most often in patients with non-small cell lung cancer," said Charles M. Baum, M.D., Ph.D., president and CEO, Mirati. "In this dose escalation phase, MGCD516 was well tolerated and showed favorable PK characteristics in unselected cancer patients. Later this year we will begin treating selected patients with solid tumors, including non-small cell lung cancer."
Study links air pollution to increased colorectal cancer risk through DNA changes